Navigation Links
Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference
Date:5/22/2013

BUFFALO, N.Y., May 22, 2013 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Second Annual Marcum LLP Microcap Conference, May 30, in New York, NY.

Neil Lyons , CPA, Chief Financial Officer of Cleveland BioLabs, will present the Company's oncology and biodefense programs on May 30 at 1:30 p.m. Eastern Time.  A live and archived webcast of the Company's presentation will be available on the Investors page of the Cleveland BioLabs website at www.cbiolabs.com.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging deep mechanistic understanding of the cell death process, apoptosis, to develop a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. The Company's lead compound is being developed as both a radiation countermeasure and a cancer treatment. The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children's Cancer Institute Australia and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, '/>"/>

SOURCE Marcum LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ganeden Biotech® Moves Its State-Of-The-Art Lab To Its World Headquarters In Cleveland
2. New England Biolabs Releases the NEBNext Microbiome DNA Enrichment Kit
3. New England Biolabs opens seventh subsidiary in Singapore
4. New England Biolabs New Website Adds Technical Information, Easy Ordering, and Better Search
5. NIH Awards New England Biolabs a Phase II SBIR Grant for the Research and Development of Novel Enzymes for Epigenetic Studies
6. New England Biolabs Develops Novel Polymerase with Ultra-High Fidelity and Minimal GC Bias
7. New England Biolabs Demonstrates Support for Interactive Scientific Literature by Collaborating with AQnowledge
8. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
9. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
10. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
11. Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... announced the release of a groundbreaking new version of its flagship DNA design ... methodology breaks down complex DNA sequences into numerous genetic parts, which in turn ...
(Date:8/31/2015)... Pune (PRWEB) , ... August 31, 2015 , ... ... in various industries because of its properties such as low carbon footprints and ... by the use of petroleum based plastics. On the basis of applications, the ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Sensors market is estimated at $0.19 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Biology Technology:GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4
... MannKind Corporation (Nasdaq: MNKD ) today ... Inc. (NYSE: PFE ) to purchase Pfizer,s ... and assets related to the production of bulk insulin, ... a quantity of bulk insulin and a license to ...
... computational resources the idea of a computational laboratory ... conceptual and technical challenges. Chief among these is ... of incomplete knowledge and information, reflected in observed ... has, in recent years, grown from a collection ...
... a leading medical device/biopharmaceutical company located in Santa Ana, ... CHO-CD XP(TM) Culture System to their cell culture product ... set of chemically-defined*, serum-free, and animal component free media ... and production for recombinant CHO cell lines. It ...
Cached Biology Technology:MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 2MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 3MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant 4Opportunities and challenges in uncertainty quantification for complex interacting systems 2Irvine Scientific Launches IS CHO-CD XP(TM) 2
(Date:8/12/2015)... CORAL SPRINGS, Florida , August 12, 2015 /PRNewswire/ ... globally, the pace of mobile payment innovation and advanced ... continues to replace the way consumers rely on using ... forges ahead with reinventing the future for payment services ... Inc. (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... a big killer, responsible for more than 35,000 deaths in ... with the deadly H5N1 strain of bird flu are gradually ... scientists are discussing ways to better understand the flu and ... modify flu as a bioweapon to make it even more ...
... Cigarette smoke can turn normal breast cells cancerous by ... development, University of Florida scientists report. , While some ... damaged DNA, many others become unable to access their ... a UF study published today (Aug. 21) in the ...
... here reveals that a new strain of mice offers the ... leukemia and should greatly aid the development of new drugs ... transgenic mouse, develops a malignancy that closely mimics chronic lymphocytic ... hampered the development of new treatments for CLL as well ...
Cached Biology News:Scientists aim to thwart use of flu as bioweapon 2Scientists aim to thwart use of flu as bioweapon 3Cigarette smoke blocks cell repair mechanism, University of Florida study shows 2Cigarette smoke blocks cell repair mechanism, University of Florida study shows 3Mouse mimics chronic leukemia, will aid drug development 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: